US-based biotech startup Helex has raised $3.5 million in a seed funding round to advance its groundbreaking preclinical program targeting genetic kidney diseases.
This significant investment, led by pi Ventures and supported by investors like Bluehill.VC and SOSV, marks a pivotal moment for the company as it aims to address critical unmet needs in kidney care.
Helex’s Mission to Transform Kidney Disease Therapy
Founded in 2021, Helex is headquartered in New York with operations in Hyderabad, India, and focuses on developing targeted genomic medicines using proprietary lipid nanoparticle (LNP) delivery systems and artificial intelligence.
The company’s lead program targets Autosomal Dominant Polycystic Kidney Disease (ADPKD), a progressive genetic disorder affecting over 12 million people worldwide.
ADPKD is a leading cause of chronic kidney disease, impacting nearly 5% of CKD patients in India alone, highlighting the urgent need for innovative therapies.
A Glimpse into Helex’s Innovative Approach
Helex leverages cutting-edge CRISPR technology to enhance the precision and safety of gene editing, positioning itself as a frontrunner in non-viral gene therapies.
With over $6 million raised to date, the latest funding will accelerate the preclinical development of its lead candidate, bringing hope to millions lacking effective treatment options.
The Broader Impact on Global Health
The impact of Helex’s work could be transformative, as kidney diseases remain a significant global health burden, often leading to dialysis or transplantation.
Historically, treatments for genetic kidney disorders have been limited, with patients facing high costs and low accessibility to care, especially in developing regions.
Looking ahead, Helex’s advancements could pave the way for more affordable and precise therapies, potentially reducing the long-term healthcare burden on societies.
As the biotech sector continues to grow, Helex stands out as a promising player, with plans to expand its pipeline and eventually move into clinical trials.
For now, the focus remains on rigorous preclinical testing to ensure safety and efficacy, a critical step before bringing life-changing solutions to patients.
Andrew Lee
